Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Last trade$1.41
Day change-$0.005 (-0.35%)
Day range$1.36 – $1.55
Volume1,122,754
Market cap$169M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$168.65M
Price / earnings
—
Price / book
4.08×
Price / sales
15.28×
EV / sales
14.93×
EV / EBITDA
-1.93×
Profitability
Earnings per share
-$0.72
Return on assets
-112.95%
Return on equity
-209.85%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.96×
Quick ratio
2.96×
Cash ratio
0.19×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$70.93M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PYXS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$11.04M
$0
$2.82M
$0
$0
Cost of revenue
$0
$0
$0
$2.39M
$0
$0
$0
$0
Gross profit
$0
$0
$0
$8.65M
$0
$2.82M
$0
$0
Selling, general and administrative
$3.97M
$9.93M
$4.38M
$5.23M
$5.65M
$5.44M
$5.87M
$5.08M
Research and development
$16.56M
$16.06M
$19.98M
$21.71M
$17.81M
$17.13M
$17.04M
$14.02M
Total operating expenses
$20.52M
$25.99M
$24.36M
$26.95M
$23.46M
$22.57M
$22.91M
$40.07M
Operating income
-$20.52M
-$25.99M
-$24.36M
-$18.3M
-$23.46M
-$19.75M
-$22.91M
-$40.07M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$19.98M
-$25.35M
-$23.27M
-$17M
-$22M
-$18.07M
-$21.16M
-$37.74M
Income taxes
$0
$0
$0
$1.1M
$0
$283K
$0
-$2.16M
Net income
-$19.98M
-$25.35M
-$23.27M
-$18.11M
-$22M
-$18.35M
-$21.16M
-$35.57M
Net income attributable to common shareholders
-$19.98M
-$25.35M
-$23.27M
-$18.11M
-$22M
-$18.35M
-$21.16M
-$35.57M
EBITDA
-$20.22M
-$25.69M
-$23.9M
-$15.4M
-$22.93M
-$19.22M
-$22.36M
-$18.56M
Basic earnings per share
-$0.24
-$0.40
-$0.37
-$0.29
-$0.35
-$0.30
-$0.35
-$0.58
Diluted earnings per share
-$0.24
-$0.40
-$0.37
-$0.29
-$0.35
-$0.30
-$0.35
-$0.58
Recent news
Company coverage with links to the original publishers.
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 89,530 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 111,913 shares of Pyxis Oncology’s common stock to five newly hired employees. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of June 28, 2024, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) since 2015.
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, June 6, 2024 at 9:00 AM Eastern Time at the Jefferies Global Healthcare Conference in New York City, where members of management will also host investor one-on-one meetings.
Pyxis Oncology (PYXS) delivered earnings and revenue surprises of 77.78% and 279.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The average of price targets set by Wall Street analysts indicates a potential upside of 61.3% in Pyxis Oncology (PYXS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.